LSTA
Lisata TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
At a $3.23 anchor price, LSTA trades well below the signed $5.00 cash merger consideration, so any credible evidence that Kuva financing is secured and the tender will launch can compress the spread quickly; the revised merger terms are economically better than the earlier $4.00 term-sheet headline [#8-K-2026-04-15].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
CVR value is contingent and may never be realized even if the cash deal closes.
Momentum
57
Value
41
Sentiment
41
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.40 · Bull $5.25 · Bear $1.20
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-29 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $4.00
Why
Momentum57 · Δ7d -
Value41 · Δ7d +0.1
Sentiment41 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
57
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
41
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 57.0 / Value 41.1 / Sentiment 40.7
Fundamentals (TTM)As of 2026-05-29
Fundamentals (TTM)
As of 2026-05-29
Market Cap
$29.6M
Beta
1.21
Shares Out
8.82M
P/E (TTM) · Derived
-1.4
P/S (TTM)
15.91
P/FCF (TTM) · Derived
-1.67
Rev YoY
-
EPS YoY
+17.9%
Gross Margin
-
Op Margin
-1876.4%
Net Debt
-$31.25M
Current Ratio
4.72
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology